Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 14/20 | 0.56 |
| ▸ | PDE4B | Q07343 | 14/20 | 0.56 |
| ▸ | PDE4C | Q08493 | 14/20 | 0.56 |
| ▸ | PDE4D | Q08499 | 14/20 | 0.56 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.48 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.39 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6760292 | 0.86 | PDE4A (0.46) | PDE4APDE4BPDE4CPDE4DALOX5 | |
| SCHEMBL5636904 | 0.86 | PDE4B (0.44) | PDE4APDE4BPDE4CPDE4DALOX5 | |
| SCHEMBL5533925 | 0.84 | MAPT (0.46) | PDE4APDE4BPDE4CPDE4DALOX5 | |
| SCHEMBL7675615 | 0.81 | PDE4A (0.46) | PDE4APDE4BPDE4CPDE4DALOX5 | |
| SCHEMBL5888118 | 0.77 | PDE4A (0.46) | PDE4APDE4BPDE4CPDE4DALOX5 | |
| SCHEMBL13111735 | 0.73 | PDE4A (0.63) | PDE4APDE4BPDE4CPDE4DP2RX7 | |
| Awd-12-281 SCHEMBL155120 | 0.72 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DP2RX7 | |
| Awd-12-281 SCHEMBL29413256 | 0.72 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DP2RX7 | |
| SCHEMBL5532547 | 0.72 | MAPT (0.45) | POLBMAPTSAE1UBA2 | |
| Awd-12-281 SCHEMBL5638122 | 0.71 | PDE4A (0.98) | PDE4APDE4BPDE4CPDE4DPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1526870-A1 | NOVEL COMBINATION OF GLUCOCORTICOIDS AND PDE-4-INHIBITORS FOR TREATING RESPIRATORY DISEASES, ALLERGIC DISEASES, ASTHMA AND COPD | VIATRIS GmbH & Co. KG (DE) | 2005-05-04 | — | — | EP | claimed |
| US-20040220183-A1 | inhibiting tumor necrosis factor; respiratory system disorders; prevent neutrophil infiltration in lungs; skin disorders | HOFGEN NORBERT (DE) | 2004-11-04 | — | — | US | claimed |
| EP-1404369-A1 | COMPOSITION COMPRISING A PDE-4 INHIBITOR AND H1-RECEPTOR ANTAGONIST AND THE USE THEREOF FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF RESPIRATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2004-04-07 | — | — | EP | claimed |
| WO-2004019984-A1 | NOVEL COMBINATION OF GLUCOCORTICOIDS AND PDE-4-INHIBITORS FOR TREATING RESPIRATORY DISEASES, ALLERGIC DISEASES, ASTHMA AND COPD | VIATRIS GMBH & CO. KG (DE) | 2004-03-11 | — | — | WO | claimed |
| WO-2003000289-A1 | COMPOSITION COMPRISING A PDE-4 INHIBITOR AND H1-RECEPTOR ANTAGONIST AND THE USE THEREOF FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF RESPIRATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2003-01-03 | — | — | WO | claimed |
| EP-3039126-A2 | SMALL MOLECULE CELLULAR REPROGRAMMING TO GENERATE NEURONAL CELLS | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone (US) | 2016-07-06 | — | — | EP | disclosed |
| WO-2015041809-A2 | SMALL MOLECULE CELLULAR REPROGRAMMING TO GENERATE NEURONAL CELLS | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2015-03-26 | — | — | WO | disclosed |
| EP-2736886-A1 | SUBSTITUTED QUINOLINES AND THEIR USE AS MEDICAMENTS | Boehringer Ingelheim International GmbH (DE) | 2014-06-04 | — | — | EP | disclosed |
| WO-2013014060-A1 | SUBSTITUTED QUINOLINES AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-31 | — | — | WO | disclosed |
| EP-1888033-A2 | METHOD AND COMPOSITION FOR TREATING INFLAMMATORY DISORDERS | Biolipox AB (SE) | 2008-02-20 | — | — | EP | disclosed |
| WO-2007123699-A1 | METHODS AND COMPOSITIONS FOR MODULATING MELANOGENESIS BY USING A MCLR AGONIST | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2007-11-01 | — | — | WO | disclosed |
| WO-2006131737-A2 | METHOD AND COMPOSITION FOR TREATING INFLAMMATORY DISORDERS | BIOLIPOX AB (SE) | 2006-12-14 | — | — | WO | disclosed |
| WO-2006062817-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PERIPHERAL B-CELL NEOPLASMS | BOSTON MEDICAL CENTER CORPORATION (US) | 2006-06-15 | — | — | WO | disclosed |
| EP-1660086-A2 | COMBINATION OF GH SECRETAGOGUES AND PDE4 INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME LTD. (GB) | 2006-05-31 | — | — | EP | disclosed |
| EP-1526870-A1 | NOVEL COMBINATION OF GLUCOCORTICOIDS AND PDE-4-INHIBITORS FOR TREATING RESPIRATORY DISEASES, ALLERGIC DISEASES, ASTHMA AND COPD | VIATRIS GmbH & Co. KG (DE) | 2005-05-04 | — | — | EP | disclosed |
| WO-2004087157-A2 | COMBINATION OF GH SECRETAGOGUES AND PDE4 INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME LIMITED (GB) | 2004-10-14 | — | — | WO | disclosed |
| WO-2004019984-A1 | NOVEL COMBINATION OF GLUCOCORTICOIDS AND PDE-4-INHIBITORS FOR TREATING RESPIRATORY DISEASES, ALLERGIC DISEASES, ASTHMA AND COPD | VIATRIS GMBH & CO. KG (DE) | 2004-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220183-A1 | inhibiting tumor necrosis factor; respiratory system disorders; prevent neutrophil infiltration in lungs; skin disorders | MMP8, MPO, TNF | PDE4A 7/4885PDE4B 21/4885PDE4C 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.